164 related articles for article (PubMed ID: 19713745)
21. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
22. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
23. Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.
El-Naggar AM; Veinotte CJ; Cheng H; Grunewald TG; Negri GL; Somasekharan SP; Corkery DP; Tirode F; Mathers J; Khan D; Kyle AH; Baker JH; LePard NE; McKinney S; Hajee S; Bosiljcic M; Leprivier G; Tognon CE; Minchinton AI; Bennewith KL; Delattre O; Wang Y; Dellaire G; Berman JN; Sorensen PH
Cancer Cell; 2015 May; 27(5):682-97. PubMed ID: 25965573
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
[TBL] [Abstract][Full Text] [Related]
25. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
26. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
[TBL] [Abstract][Full Text] [Related]
27. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
[TBL] [Abstract][Full Text] [Related]
28. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.
Berquin IM; Pang B; Dziubinski ML; Scott LM; Chen YQ; Nolan GP; Ethier SP
Oncogene; 2005 Apr; 24(19):3177-86. PubMed ID: 15735691
[TBL] [Abstract][Full Text] [Related]
29. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia Induces a HIF-1-Dependent Transition from Collective-to-Amoeboid Dissemination in Epithelial Cancer Cells.
Lehmann S; Te Boekhorst V; Odenthal J; Bianchi R; van Helvert S; Ikenberg K; Ilina O; Stoma S; Xandry J; Jiang L; Grenman R; Rudin M; Friedl P
Curr Biol; 2017 Feb; 27(3):392-400. PubMed ID: 28089517
[TBL] [Abstract][Full Text] [Related]
31. Fusion of macrophages promotes breast cancer cell proliferation, migration and invasion through activating epithelial-mesenchymal transition and Wnt/β-catenin signaling pathway.
Zhang LN; Huang YH; Zhao L
Arch Biochem Biophys; 2019 Nov; 676():108137. PubMed ID: 31605677
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.
Lv ZD; Kong B; Li JG; Qu HL; Wang XG; Cao WH; Liu XY; Wang Y; Yang ZC; Xu HM; Wang HB
Oncol Rep; 2013 Jan; 29(1):219-25. PubMed ID: 23129177
[TBL] [Abstract][Full Text] [Related]
33. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells.
Basaki Y; Taguchi K; Izumi H; Murakami Y; Kubo T; Hosoi F; Watari K; Nakano K; Kawaguchi H; Ohno S; Kohno K; Ono M; Kuwano M
Eur J Cancer; 2010 Mar; 46(5):954-65. PubMed ID: 20079629
[TBL] [Abstract][Full Text] [Related]
34. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
Janz M; Harbeck N; Dettmar P; Berger U; Schmidt A; Jürchott K; Schmitt M; Royer HD
Int J Cancer; 2002 Jan; 97(3):278-82. PubMed ID: 11774277
[TBL] [Abstract][Full Text] [Related]
35. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Palafox M; Ferrer I; Pellegrini P; Vila S; Hernandez-Ortega S; Urruticoechea A; Climent F; Soler MT; Muñoz P; Viñals F; Tometsko M; Branstetter D; Dougall WC; González-Suárez E
Cancer Res; 2012 Jun; 72(11):2879-88. PubMed ID: 22496457
[TBL] [Abstract][Full Text] [Related]
36. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD
Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370
[TBL] [Abstract][Full Text] [Related]
37. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
38. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
39. Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transition.
Tseng WC; Chuang CW; Yang MH; Pan CC; Tarng DC
Urol Oncol; 2016 Nov; 34(11):485.e15-485.e24. PubMed ID: 27519276
[TBL] [Abstract][Full Text] [Related]
40. PRPF4 is a novel therapeutic target for the treatment of breast cancer by influencing growth, migration, invasion, and apoptosis of breast cancer cells via p38 MAPK signaling pathway.
Park S; Han SH; Kim HG; Jeong J; Choi M; Kim HY; Kim MG; Park JK; Han JE; Cho GJ; Kim MO; Ryoo ZY; Choi SK
Mol Cell Probes; 2019 Oct; 47():101440. PubMed ID: 31445970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
